AGC Biologics has appointed Axel Schleyer as senior vice president of Business Development, North America, and Christoph Winterhalter as senior vice president of Business Development, Europe. Mr. Schleyer and Mr. Winterhalter will report to Robert Broeze, chief business officer.

Mr. Schleyer brings more than 17 years of leadership experience in business development and key account management for pharmaceutical, biotechnology, and contract manufacturing organizations. He most recently served as vice president of Business Development – Americas & Asia/Pacific at Boehringer Ingelheim, where he was responsible for driving business efforts and strategic direction with an emphasis on the US and Asia, as well as establishing strong operational presence and strengthening international market awareness.

Mr. Winterhalter brings more than 20 years of business development leadership experience within Life Sciences organizations throughout Europe and the US. He most recently served as senior vice president at Rentschler Biotechnologie GmbH, where he was responsible for global strategy development and execution, development of new business models, account management, and cultivation of key alliances.

AGC Biologics recently announced its new brand name in early January 2018. Under the AGC Biologics name, and with the support of Mr. Schleyer and Mr. Winterhalter, the company will maintain and grow its global presence with microbial and mammalian capabilities, fulfilling early-phase through commercial production, both at small and large-scale.

“This is a very exciting time for AGC Biologics, as we continue to rapidly expand our capabilities and global presence in the CDMO marketplace,” said Bob Broeze, chief business officer. “Axel Schleyer and Christoph Winterhalter each add tremendous value to our growing business development team, and their considerable experience and expertise will further facilitate our progression as a proven industry leader.”